2. The Mortality Stats

The list burned in her handbag for three days.

Priya sat in her rented room in Tejaswini Nagar's old quarter, the ceiling fan stirring the humid air without cooling it, and stared at Anjali's folded paper as if it might reveal its secrets through sheer intensity of scrutiny. Five names. Five dates. Five room numbers. And that trembling postscript: The trial never ended.

She had spent the first day verifying the names. It had been easier than she expected—obituaries in the Sundara Chronicle's digital archive, death notices filed with the municipal corporation, a few discreet phone calls to families who were bewildered but not suspicious. Their loved ones had been old, after all. The body fails. The heart stops. Grief, in these cases, came wrapped in a shroud of inevitability.

But the pattern was undeniable.

Mr. R. Iyer, Room 12, died April 3rd. Age seventy-six. Cause of death: cardiac arrest. Mrs. L. Fernandes, Room 14, died May 18th. Age seventy-four. Cause of death: respiratory failure. Mr. A. Ghosh, Room 9, died June 7th. Age seventy-eight. Cause of death: cardiac arrest. Mrs. K. Menon, Room 16, died July 22nd. Age seventy-two. Cause of death: stroke. And now Uncle Nikhil, Room 17, died September 2nd. Age seventy-three. Cause of death: cardiac arrest.

Five deaths in six months, all in the east wing, all within rooms clustered around a single corridor. All of them participants in something called the "longevity study." All of them receiving weekly injections.

Statistical probability was not on the side of coincidence.

On the second day, Priya had visited the office of the Sundara Pradesh Medical Council's public records division. The clerk, a harried woman with spectacles perched on her greying head, had pulled the files on PharmaGenexia's approved clinical trials in the state. There it was, buried among dozens of other applications: Trial Protocol PGX-LON-2023, a Phase II study of a compound called "GerontoVive," described as a "gene-therapeutic supplement designed to enhance cellular regeneration in geriatric populations." The trial had been approved for a six-month duration, from January to June 2024, at three sites across Sundara Pradesh. The Gilded Oaks Sanctuary was listed as Site A.

The trial had concluded in June 2024. All approvals had lapsed. The final report, submitted by Dr. Arvind Kapadia as principal investigator, declared "no significant adverse events" and recommended progression to Phase III.

But the deaths had begun in April 2025. Eleven months after the trial had supposedly ended.

Priya had copied the files, thanked the clerk, and returned to her room to think. The disconnect nagged at her. If the trial was over, why were residents still receiving injections? If the compound was safe, why were healthy elders dying at an accelerating rate? And if Dr. Kapadia had reported no adverse events, why had Anjali spoken of secrecy and surveillance?

She needed to get inside The Gilded Oaks again. Not as a grieving relative this time, but as someone who could move through the institution without attracting attention. Someone with a legitimate reason to ask questions.

On the morning of the fourth day, Priya walked into the offices of the Sundara Chronicle, the newspaper that had fired her two years ago, and requested a meeting with the features editor. Her former colleague, a weary man named Ramesh Nair who had somehow survived three rounds of layoffs, regarded her across his cluttered desk with the expression of a man who had seen too many idealists crash against the rocks of corporate reality.

"You want a freelance assignment," Ramesh said flatly. "To write a profile of a retirement home."

"A lifestyle piece," Priya said, keeping her voice bright and unthreatening. "The rise of luxury elder care in coastal Sundara Pradesh. The Gilded Oaks Sanctuary as a case study. Very positive, very uplifting. The kind of thing your advertisers will love."

Ramesh raised an eyebrow. "You hated writing puff pieces. That's why you got fired."

"I've matured."

"No, you haven't." Ramesh leaned back in his chair, which creaked in protest. "What are you really doing, Priya?"

She considered lying, but Ramesh had always been able to see through her. "There's a story," she said quietly. "Something wrong at that place. I don't know what yet, but I need a cover to find out."

Ramesh was silent for a long moment. Outside his office window, the monsoon rain had begun again, streaking the glass with silver lines. Finally, he pulled a press credential from his desk drawer and slid it across the table.

"This is a temporary assignment," he said. "One week. You file a soft-focus profile suitable for the Sunday supplement, and whatever else you find, you keep the Chronicle out of it until you have proof that would stand up in court. I'm not risking my pension for your hunches."

"Understood."

"One more thing." Ramesh's voice dropped. "Be careful. PharmaGenexia is one of the largest advertisers in the state. They sponsor half the medical conferences in Sundara Pradesh. They fund politicians on both sides of the aisle. If you're going to poke this particular beast, make sure your poking stick is very, very long."

Priya tucked the press credential into her bag, next to Anjali's list. "I always am."

She made two stops before returning to The Gilded Oaks. The first was at a medical supply shop in the old market district, where she purchased a white lab coat, a clipboard, and a box of surgical masks—the universal uniform of medical anonymity. The second was at the Tejaswini Nagar Central Library, where she spent three hours reading back issues of pharmaceutical trade journals and downloading every published paper she could find authored by Dr. Arvind Kapadia.

The papers were illuminating. Kapadia's early research, from his days at the All-Sundara Institute, focused on gene therapies for age-related macular degeneration. Solid work, well-regarded, nothing controversial. But around 2019, his focus had shifted. He had begun publishing on something called "targeted viral vector delivery systems"—a technique that used modified viruses to carry therapeutic genes into specific cell types. The language grew more technical, more guarded. Funding acknowledgments shifted from government research grants to PharmaGenexia's corporate R&D division.

By 2023, Kapadia was listed as a co-inventor on a PharmaGenexia patent for a "method of inducing controlled apoptosis in senescent cells." Apoptosis. Programmed cell death. The patent described a viral vector that would activate only in cells with shortened telomeres—the caps on chromosomes that shrink as cells age. When activated, the vector would trigger a cascade of cellular self-destruction, clearing out old cells to make way for new ones.

In theory, it was elegant. Remove senescent cells, rejuvenate tissue, extend healthy lifespan. In theory.

But Priya's research also turned up a series of letters to the editor in the Sundara Pradesh Journal of Medical Ethics, written by a Dr. Meera Nambiar, who had been a senior researcher at PharmaGenexia until her abrupt departure in 2024. The letters were cautious, academic in tone, but their implications were damning. Dr. Nambiar had raised concerns about the specificity of the viral vector. About what happened when the vector encountered cells with damaged DNA—cancerous cells, or cells stressed by infection or environmental toxins. About the possibility of off-target effects in organs with high cellular turnover: the liver, the kidneys, the heart muscle.

"A therapy designed to eliminate senescent cells may, under certain physiological conditions, trigger apoptotic cascades in healthy tissue," Dr. Nambiar had written in her final published letter, dated February 2024. "The current Phase II protocol lacks adequate monitoring for delayed cardiotoxic events. I urge the ethics committee to require extended follow-up before approving progression to Phase III."

The ethics committee had not required extended follow-up. PharmaGenexia had terminated Dr. Nambiar's employment three weeks later, citing "irreconcilable professional differences." And Phase III had proceeded without her.

Priya closed the last journal volume and sat in the library's fluorescent silence, her mind connecting dots. A gene therapy designed to kill senescent cells. A viral vector that might not distinguish between old cells and vulnerable ones. A series of sudden cardiac deaths in elderly patients who had been healthy until they weren't. And Dr. Arvind Kapadia, whose signature appeared on every document, every approval, every reassuring report to the regulators.

The trial hadn't ended. It had simply gone underground.

Dressed in her white coat with the press credential tucked into a pocket, Priya returned to The Gilded Oaks Sanctuary that afternoon. This time, she did not enter through the front gate. She drove around to the service entrance, where deliveries arrived and staff came and went without the scrutiny accorded to visitors and family members.

The security guard at the service gate was a young man with the bored expression of someone whose job consisted mostly of waiting. He glanced at her coat, her clipboard, her press credential with the Sundara Chronicle logo prominently displayed.

"PharmaGenexia follow-up," Priya said, her voice clipped and professional. "I need to audit the injection logs for the longevity study participants."

The guard blinked. "I don't have authorization for—"

"It's a regulatory compliance visit." Priya tapped her clipboard. "I can call Dr. Kapadia directly if you prefer, but he's in a board meeting and he specifically asked not to be disturbed for routine inspections. This is routine. Unless you want to be the person who interrupts his meeting?"

The guard hesitated. Priya held his gaze, projecting the calm authority of a woman who belonged exactly where she was. After a long moment, he stepped aside.

"Staff entrance is through the loading dock," he said. "Sign in at the nursing station on the second floor."

"Thank you."

The loading dock was busy with the ordinary commerce of institutional life—boxes of medical supplies, crates of fresh produce, linens wrapped in plastic. No one looked twice at a woman in a white coat carrying a clipboard. Priya walked past the kitchen entrance, past the laundry, and into a service elevator that smelled faintly of bleach and old flowers.

The east wing corridor was quiet when she stepped out. The same hushed, listening quiet she had noticed on the day of Uncle Nikhil's funeral. Priya walked slowly, counting room numbers. Room 12, Mr. Iyer's room, now occupied by a new resident. Room 14, Mrs. Fernandes's room, the door slightly ajar, a television murmuring inside. Room 9, Room 16, Room 17—Uncle Nikhil's room, still empty, the brass nameplate holder bare.

She was looking for the injection logs. If the longevity study was still running in secret, there had to be records. Dosage charts, patient monitoring forms, blood work results. Somewhere in this building, someone was tracking the data.

The nursing station on the east wing was a glass-walled cubicle positioned at the intersection of three corridors. A single nurse sat inside, her back to the door, focused on a computer screen. Priya could see her reflection in the monitor—a middle-aged woman with a weary posture, typing slowly with two fingers.

Priya knocked on the doorframe. "Excuse me. I'm from PharmaGenexia compliance. Dr. Kapadia asked me to review the GerontoVive administration records."

The nurse turned. It was not Anjali, but a woman Priya didn't recognize, her face round and placid, her uniform crisp. "I wasn't informed of any audit," she said, frowning.

"It's unscheduled. Quality assurance spot-check." Priya smiled apologetically. "I know it's inconvenient. I just need to see the logs for the east wing participants from the past six months. It shouldn't take more than ten minutes."

The nurse's frown deepened. "I'll need to call Dr. Kapadia."

"Of course. Please do."

Priya's heart hammered as the nurse reached for the phone. If Kapadia answered, her cover would be blown. But the phone rang four times, five times, and went to voicemail. The nurse hung up, looking unsettled.

"He must still be in his meeting," Priya said smoothly. "Look, I understand your caution. I can wait here while you pull the records, or I can come back tomorrow with written authorization from PharmaGenexia's legal department. But my supervisor is going to ask why a routine spot-check took two visits, and I'd rather not have to explain that to him."

The nurse wavered. Priya could see the calculation in her eyes—the desire to follow protocol warring with the fear of causing trouble for Dr. Kapadia, who was known to have a temper. Finally, the nurse stood.

"The logs are in the medical records room," she said. "I can show you, but you can't remove anything from the premises."

"Standard procedure. I just need to verify the signature pages."

The medical records room was in the basement, accessible by another service elevator. It was a windowless space lined with metal filing cabinets, each drawer labeled with dates and study codes. The nurse unlocked the cabinet marked PGX-LON-2023 - Site A - Active and pulled out a thick binder.

"These are the current records," she said. "I'll need to stay while you review them."

Priya opened the binder. Inside were neatly organized sheets—patient intake forms, consent documents signed by family members, weekly injection logs with dates and dosages and the initials of the administering nurse. She flipped through the pages, her trained eyes scanning for patterns.

The consent forms were the first red flag. They were signed not by the residents themselves, but by family members acting as medical proxies. The signatures varied, but the dates were clustered. And the language of the forms was dense, technical, filled with legal disclaimers that most families would not have understood.

The injection logs were worse. Priya counted fourteen names listed as active participants—five of them now deceased, their names marked with a small red cross. And the dosage column showed something strange. The injections were supposed to be a standard maintenance dose, according to the original trial protocol. But in the log, the doses varied widely. Some residents received 2 milliliters. Others received 5 milliliters. Uncle Nikhil's last dose, administered three days before his death, had been 10 milliliters.

Double the maximum protocol dosage.

Priya's hands were steady as she turned the pages, but her mind was racing. This wasn't a continuation of the original trial. This was something else—an experiment with dosages, with delivery methods, with the boundaries of what the human body could tolerate before it broke.

"The deceased participants," Priya said, keeping her voice neutral. "Were autopsies performed?"

The nurse shifted uncomfortably. "Dr. Kapadia determined that autopsies weren't necessary. The causes of death were clearly natural."

"But they were enrolled in a clinical study."

"The study was completed last year. These are... compassionate use extensions."

Priya looked up. "Compassionate use. For a drug that hasn't completed Phase III trials. With variable dosages. And no post-mortem analysis."

The nurse said nothing. Her face had gone very still.

Priya closed the binder and returned it to the filing cabinet. "Thank you for your cooperation. I'll include a note in my report that the records were properly maintained."

She walked out of the medical records room, up the service elevator, and out of The Gilded Oaks without looking back. But as she passed through the service gate, she caught a glimpse of a familiar figure in the main courtyard—Dr. Arvind Kapadia, his meeting apparently concluded, speaking with Inspector D'Souza. Both men were laughing. D'Souza's hand rested on Kapadia's shoulder with the easy familiarity of old friends.

Priya drove back to her rented room through streets slick with fresh rain. That night, she sat at her desk and spread out all the materials she had gathered: Anjali's list, the trial protocol documents, Dr. Nambiar's ethical objections, the injection logs with their escalating dosages. She had enough to raise questions. She did not yet have enough to prove murder.

But there was one person who might know more. One person who had tried to warn the ethics committee and been silenced for her trouble.

Priya opened her laptop and began searching for Dr. Meera Nambiar's current contact information. It took two hours and three password-protected databases to find an address: a small coastal village called Urva Kere, fifty kilometers south of Tejaswini Nagar, where Dr. Nambiar had retreated after her dismissal from PharmaGenexia.

She would go tomorrow. She would find the disgraced researcher and learn what had really happened in the laboratory. And then she would decide what to do with the knowledge that was accumulating in her hands like unlit dynamite.

Outside her window, the monsoon rain fell without ceasing, washing the streets clean and filling the gutters with the detritus of the day. In the distance, lightning flickered over the Arabian Sea, illuminating the darkness for a single frozen moment before the thunder rolled in, deep and resonant, like a warning bell tolling in the depths of the storm.